SOPHiA DDM™
for Myeloid Malignancies

Confidently identify the genomic drivers of myeloid malignancies

Leverage up‑to‑date NGS‑based applications and the analytical power of the SOPHiA DDM™ Platform to accurately characterize the complex mutational profile of myeloid tumors, accelerating the study of biomarkers and disease‑associated genes.

Request a Demo

Overview Key Features Workflow Analytics Applications Resources

OVERVIEW

Resolve complex variants in myeloid disease

Myeloid malignancies (MDS, MPN, AML, and CML among others) arise from highly heterogeneous and complex genomic mutations. Advanced molecular technologies, like next‑generation sequencing (NGS), are essential to generate an accurate molecular profile of each individual and obtain critical insights quickly.

VIEW THE WEBINAR

Chart a course for better outcomes

The SOPHiA DDM™ Platform empowers experts with high‑quality, data analysis that enables easy variant detection, annotation, and classification for the study of myeloid malignancies.

Optimize the analysis of raw genomic data to rapidly and accurately identify biologically relevant variants, accelerating research and enhancing decision‑making.

Easily navigate complex analysis

SOPHiA DDM™ for Blood Cancers simplifies analysis of genomic drivers in hematological cancers using the trusted analytical performance and advanced features of the SOPHiA DDM™ platform.

Streamline raw genomic data analysis to precisely detect, annotate, and prioritize even the most complex blood cancer variants.

Identify challenging myeloid biomarkers

SOPHiA DDM™
Myeloid Plus Solution (MYS+)

The SOPHiA DDM™ MYS+ provides a streamlined workflow to analyze 30 genes associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia, along with 118 gene fusions linked to leukemia.

SOPHiA DDM™
Dx Myeloid Solution (CE‑IVD)

The SOPHiA DDM™ Dx Myeloid Solution is an IVD application that identifies variants in 30 genes associated with myeloid neoplasms, targeting specific mutation‑prone positions within the genome to enable data‑driven therapy decisions.

SOPHiA DDM™
Extended Myeloid Solution (ExtMYS)

The SOPHiA DDM™ ExtMYS is a capture‑based application designed to assess 98 genes associated with leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms, and more.

SOPHiA DDM™
Community Myeloid Solutions

Our Community Myeloid Solutions are NGS‑based applications, developed with and for experts like you to accurately analyze fusion events and key myeloid markers relevant for your laboratory.

KEY FEATURES

Raise your analytical capabilities

Streamline your sample to report workflow with SOPHiA DDM™ for Myeloid Malignancies, including a comprehensive range of guideline‑driven, ready‑to‑use, and customizable NGS‑based applications to accurately define genomic profiles associated with myeloid diseases.

Assess variants in challenging regions

Leverage the optimized probe design and advanced analytical capabilities of the SOPHiA DDM™ Platform to detect challenging variants, such as tandem duplications in KMT2A and FLT3, long Indels in CALR and ASXL1, and variants in high GC regions, like exon 1 of CEBPA (over 80% GC‑content).

Pinpoint fusion events with precision

Detect confidently fusion genes, with our comprehensive DNA and RNA workflows. Identify known and novel rearrangements involving key target genes, as ABL1, CBFB, RUNX1, and PML.

Rely on guideline‑driven gene content

Follow the latest ELN and NCCN guidelines with expertly‑curated gene content to ensure no challenging biomarkers are missed.

WORKFLOW

Navigate genomic profiling with ease

Accelerate your myeloid disease analysis with a simple, adaptable and accurate workflow.

You won’t be left alone.
Enjoy comprehensive support at every step through the SOPHiA DDM™ MaxCare Program, making in-house adoption a breeze.

ANALYTICS

Accurate variant analysis

Leverage the advanced analytics capabilities of SOPHiA DDM™, powered by AI, to gain deep insights into myeloid malignancies. Our proprietary algorithms enable precise molecular characterization, driving informed data‑driven decisions.

Accurately identify single nucleotide variants (SNVs) and small insertions/deletions (Indels) associated with myeloid malignancies, even in challenging samples. PEPPER™ is a sophisticated algorithm that differentiates true signal from noise, providing you with reliable results to guide decision‑making. Notably, our algorithm enables detection of internal tandem duplications (ITDs) in FLT3 as long as 300 bp.

Technology Principles

Gain crucial insights into the genomic alterations driving myeloid malignancies with MUSKAT™. Our copy number variation (CNV) calling algorithm adapts to experimental conditions and employs double normalization to identify CNVs with a single‑exon resolution, which may be overlooked by other tools. Additionally, it facilitates the detection of partial tandem duplications in the KMT2A gene.

Technology Principles

Assess fusion events from DNA for a large range of fusion partners reaching comprehensive detection of fusion genes relevant to myeloid malignancies. CARDAMOM ensures reliable identification of prevalent fusions including BCR::ABL1; RUNX1::RUNX1T1; PML::RARA; CBFB::MYH11.

Technology Principles

Confidently interpret the clinical significance of genomic variants in myeloid malignancies with MOKA™.
Our robust annotation algorithm draws from curated databases and uses de novo predictions to assess the likely effects and pathogenicity of variants.

Technology Principles

Data‑driven decision support

Match cancer molecular profiles with the latest information to identify actionable biomarker profiles and confidently determine next steps in your research journey with our add‑on module, OncoPortal™ Knowledge Base.

SOPHiA DDM™ for Myeloid Malignancies

Accurately characterize complex biomarkers with SOPHiA DDM™.

Request a Demo

APPLICATIONS

Select the right solution for your lab

Our comprehensive portfolio offers a range of ready‑to‑use and customizable solutions that enable precise characterization of genes associated with myeloid malignancies, targeting key variants from blood or bone marrow samples.

Fact Sheet

SOPHiA DDM™ Myeloid Solution (MYS)

Fact Sheet

SOPHiA DDM™ Dx Myeloid Solution (CE‑IVD)

FLYER

SOPHiA DDM™ Myeloid v2 Community Solution

Flyer

SOPHiA DDM™ Blood Cancer Community Solution 51 genes

Fact Sheet

SOPHiA DDM™ Myeloid Plus Solution (MYS+)

Fact Sheet

SOPHiA DDM™ Extended Myeloid Solution (ExtMYS)